Slideshow
We asked several urologists about whether they advocate for PSA screening to primary care physicians in their area.
Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC